Invivyd announces initiation of DECLARATION trial evaluating VYD2311

Invivyd (IVVD) announced initiation of the DECLARATION trial evaluating VYD2311, an investigational vaccine-alternative monoclonal antibody candidate for the prevention of COVID. DECLARATION is the company’s Biologics License Application, BLA-enabling, Phase 3 randomized, triple-blind, placebo-controlled clinical trial to evaluate VYD2311 efficacy and safety in prevention of symptomatic COVID in a broad population of participants including adults and adolescents. The DECLARATION study will evaluate prevention of symptomatic COVID at three months, with either a single dose or monthly doses of VYD2311, each administered via intramuscular injection, compared to placebo.